Nov 26, 2020

Whole genome and transcriptome sequencing uncovers biomarkers predicting response to immune checkpoint inhibitors

The development of immune checkpoint inhibitors (ICI), a type of cancer therapy that helps the immune system fight tumours, was one of the most significant milestones in cancer treatment in the last decade. While ICI therapy has been used to treat different cancer types, it is not universally effective and relapsed disease occurs.

Sep 24, 2020

POG researchers uncover potential biomarkers for the treatment of advanced stage breast and colorectal cancer

Cancer is a disease of the genome, and research has shown that the genomic alterations in a tumour influence treatment response and failure. For advanced-stage breast and colorectal cancer, tumour sequencing has now uncovered key alterations that can guide clinicians in determining the best course of treatment for their patients.
Aug 06, 2020

A framework for the management of inherited genetic variation impacting cancer patients and their families

Cancer is a disease of the genome. Using data from next-generation DNA sequencing technology, genome scientists and oncologists can work together to better inform an approach to individual patient treatment planning that is more targeted and personalized than ever before. But, in the process, they can also uncover information about a patient, such as their family’s susceptibility to hereditary forms of cancer and other diseases. What should scientists and clinicians do with all of this information? A new clinical framework attempts to address this increasingly common conundrum.
Jul 07, 2020

New study illustrates benefits of long-read sequencing technology for precision oncology

Whole genome sequencing has revolutionized cancer treatment planning, enabling the rapid detection of DNA mutations not routinely screened for in the clinic. Until recently, however, scientists were limited in their ability to detect large structural genetic variants using short-read sequencing technology. But with the recent release of long-read sequencing instruments, cancer researchers have been eager to see what such technology could mean for precision oncology.

Back to top